類器官研究中的細(xì)胞因子

類器官研究中的細(xì)胞因子選擇與應(yīng)用李田子,Ph.D.

高級(jí)產(chǎn)品經(jīng)理北京義翹神州科技股份有限公司09-2024義翹神州CONTENT類器官培養(yǎng)的關(guān)鍵細(xì)胞因子“配方”1經(jīng)類器官培養(yǎng)驗(yàn)證的細(xì)胞因子2義翹神州類器官培養(yǎng)的關(guān)鍵細(xì)胞因子“配方”01義翹神州類器官研究-市場(chǎng)情況義翹神州√√√√√Homan./10.1002/adbi.202200334HanbyeolLee;etal./10.51335/organoid.2021.1.e11.Source:終端客戶可能應(yīng)用Biotchenology&Pharmaceuticalindustries主要用于建立類器官模型和類器官芯片以及基于模型的藥物開(kāi)發(fā)，藥敏反應(yīng)等Academic&ResearchinstitutesHospitals&DiagnosticCenters類器官研究-研究進(jìn)展和潛在應(yīng)用義翹神州Source:NCBI-PubMedCentralhttps://ClinicalTBasicresearchBiobankingPrecisionmedicine-Responsetodrugs-ResourcesforregenerativemedicinecoupledwithgeneticengineeringDiseasemodeling-Mechanismsofhumandiseases-InheritablegeneticdisordersDrug-screeninganalysesJihoonKim;etal./10.1038/s41580-020-0259-3.類器官研究-創(chuàng)新模型2024年8月14日,Nature刊發(fā)了一篇關(guān)于具有自體組織駐留免疫系統(tǒng)的腸道類器官（IIOs）模型傳統(tǒng)的腸道類器官主要關(guān)注上皮細(xì)胞的分化和功能，而未將免疫系統(tǒng)納入其中炎癥性腸病（IBD）和癌癥等疾病中，免疫反應(yīng)會(huì)影響疾病進(jìn)展和治療效果文獻(xiàn)中建立的類器官可能能更準(zhǔn)確地表現(xiàn)出腸道病生理的狀態(tài)義翹神州TimothyRecaldinetal./10.1038/s41586-024-07791-5.SchematicoverviewofestablishmentofautologousIIOs.腸道類器官-藥物篩選應(yīng)用場(chǎng)景疾病研究題目臨床#藥物篩選結(jié)直腸癌ProspectiveObservationontheAccuracyofinVitroScreeningofColorectalCancerChemotherapyDrugsBasedonOrganoids-ona-chipNCT04996355TheCultureofAdvanced/Recurrent/MetastaticColorectalCancerOrganoidsandDrugScreeningNCT05304741Patient-derivedOrganoidsofRAS/RAFWild-typeMetastaticRightColonCancertoTesttheSensitivityandClinicalConsistencyofCombinedTreatmentofCetuximab.NCT04906733AProspectiveMulticenterRandomizedControlledTrialoftheClinicalEfficacyofNeoadjuvantTherapyBasedonOrganoidsDrugSensitivityVersusEmpiricalNeoadjuvantTherapyintheTreatmentofAdvancedRectalCancerNCT05352165義翹神州QinyingWang;etal./10.1038/s41392-022-01194-6.RSPO-1EGFNogginWnt腸道類器官激活小腸隱窩的Wnt信號(hào)協(xié)助小腸增殖隱窩數(shù)量增多維持腸道干細(xì)胞義翹神州ToshiroSato;etal./10.1053/j.gastro.2011.07.050.腸道類器官培養(yǎng)-主要細(xì)胞因子Figure.Human-derivedorganoids類器官研究-相關(guān)細(xì)胞因子BrainBreastLungProstatePancreaticHeartIntestinalGastricLiverEGFEGFEGFEGFEGFEGFFGF2FGF2FGF2FGF2FGF2FGF2FGF2FGF7TGFB1FGF10FGF10FGF10FGF10FGF10FGF10FGF10NOGNOGNOGNOGNOGNOGNOGNOGINHBAINHBAINHBAINHBAHGFRSPO1RSPO1RSPO1RSPO1RSPO1RSPO1RSPO1OSMDKK1DKK1GDNFLIF義翹神州OVARYBRAINBREASTLUNGSKIDNEYBLADDERPROSTATEEYESINNEREARESOPHAGUSSTOMACHINTESTINEandCOLONLIVERPANCREASBenedettaArtegiani;etal./10.1093/hmg/ddy187.經(jīng)類器官培養(yǎng)驗(yàn)證的細(xì)胞因子02義翹神州細(xì)胞因子產(chǎn)品線特點(diǎn)概述GMP認(rèn)證書250+細(xì)胞因子類分子，800+細(xì)胞因子類產(chǎn)品按照ISO9001:2015和ISO13485:2016質(zhì)量管理體系要求進(jìn)行生產(chǎn)涉及免疫細(xì)胞培養(yǎng)、干細(xì)胞研究、類器官培養(yǎng)等熱門應(yīng)用領(lǐng)域覆蓋生長(zhǎng)因子、趨化因子、干擾素、白介素、淋巴因子等嚴(yán)格質(zhì)控造就更優(yōu)細(xì)胞活性高批間一致性高純度（20+GMP級(jí)細(xì)胞因子）義翹神州2024年值得關(guān)注的生長(zhǎng)因子供應(yīng)商細(xì)胞因子產(chǎn)品設(shè)計(jì)種屬多：Human、Mouse、Monkey等，盡可能滿足不同的動(dòng)物實(shí)驗(yàn)?zāi)Ｐ蛢A向于無(wú)標(biāo)簽或者小標(biāo)簽真核或者原核表達(dá)系統(tǒng)低內(nèi)毒素活性有競(jìng)爭(zhēng)力應(yīng)用場(chǎng)景數(shù)據(jù)展示義翹神州多種屬：Human、Mouse、Monkey等，盡可能滿足不同動(dòng)物實(shí)驗(yàn)?zāi)Ｐ偷男枨罅x翹神州小鼠膀胱類器官培養(yǎng)MouseBladderOrganoidsafter14daysinculture25ng/mLofRecombinantMouseKGF/FGF-7Protein(50394-M07E)wasusedfor2weeksinBMEsubmergedinmousebladdermedia.DataprovidedbyDr.YinatWashingtonUniversity,St.Louis,MO.經(jīng)過(guò)14天的培養(yǎng)：細(xì)胞因子產(chǎn)品設(shè)計(jì)LPS處理的胚狀體中胚層的生物標(biāo)志物會(huì)消失且不能分化成有功能的成骨細(xì)胞LPS處理的胚狀體會(huì)出現(xiàn)凋亡的現(xiàn)象義翹神州KavithaSivasubramaniyan;etal./10.2217/1746073.細(xì)胞因子產(chǎn)品設(shè)計(jì)低內(nèi)毒素Panel(A)showsnormal5-day-oldembryoidbodiesand(B)shows5-day-oldembryoidbodiesexposedtolipopolysaccharidesfor48h.Picturewereacquiredat10×magnifications.Cometassayshowingthedegreeofapoptosisinducedincontrolandlipopolysaccharides-treatedembryoidbodies.CD14+

monocytes

were

differentiated

into

immature

DCs

by

GM-CSF(GMP-10015-HNAH)

and

IL4(GMP-11846-HNAE)

for

6

days.

DCs

were

matured

by

TNF(GMP-10602-HNAE)

for

2

days.Immature

DCsMature

DCs義翹神州細(xì)胞因子產(chǎn)品設(shè)計(jì)應(yīng)用場(chǎng)景數(shù)據(jù)展示-1：免疫細(xì)胞應(yīng)用場(chǎng)景義翹神州產(chǎn)品詳情頁(yè)下拉：點(diǎn)開(kāi)產(chǎn)品詳情頁(yè)：細(xì)胞因子產(chǎn)品設(shè)計(jì)應(yīng)用場(chǎng)景數(shù)據(jù)展示-2：類器官應(yīng)用場(chǎng)景iPSC-derivedhumanvascularorganoids(Day7)wereculturedwithFGF2(10014-HNAE),VEGF165(11066-HNAH),EGF(10605-HNAE).Redarrowsrepresentvascularorganoids.Imagetakenat10xmagnification.DataprovidedbyDr.WangatSchoolofBasicMedicalSciencePekingUniversity義翹神州活性比較數(shù)據(jù)批間一致性數(shù)據(jù)MeasuredinacellproliferationassayusingBalb/C3T3mouseembryonicfibroblasts.EGF

(Cat#:10605-HNAE)義翹神州批次1義翹神州批次2義翹神州批次3國(guó)外知名品牌義翹神州批次1義翹神州批次2高純度（≥95%）FGF2(Cat#:10014-HNAE)VEGF165(Cat#:11066-HNAH)血管類器官培養(yǎng)類器官培養(yǎng)相關(guān)產(chǎn)品數(shù)據(jù)高純度（≥95%）類器官相關(guān)產(chǎn)品的引用文獻(xiàn)義翹神州文獻(xiàn)名稱(年份)-類器官類型影響因子所用貨號(hào)HumanearlysyncytiotrophoblastsarehighlysusceptibletoSARS-CoV-2infection(2022)-滋養(yǎng)層類器官11.710463-HNAS(HGF);11083-HNAS(RSPO1)Single-celltranscriptomicsrevealscellatlasandidentifiescyclingtumorcellsresponsibleforrecurrenceinameloblastoma(2024)-成釉細(xì)胞瘤類器官10.810014-HNAE(FGF2)CUL4B-DDB1-COP1-mediatedUTXdownregulationpromotescolorectalcancerprogression(2023)-結(jié)直腸癌類器官9.411083-HNAS(RSPO1);50688-M02H(NOG);50482-MNCH(EGF);10573-HNAE(FGF10)FeedbackactivationofEGFR/wild-typeRASsignalingaxislimitsKRASG12DinhibitorefficacyinKRASG12D-mutatedcolorectalcancer(2023)-結(jié)直腸癌類器官6.911083-HNAS(RSPO1);50688-M02H(NOG);50482-MNCH(EGF)EvaluationofB7-H3TargetedImmunotherapyina3DOrganoidModelofCraniopharyngioma(2022)-顱咽管瘤類器官4.810605-HNAE(EGF);10573-HNAE(FGF10)2022~2024類器官相關(guān)引用文獻(xiàn)數(shù)量滋養(yǎng)層類器官培養(yǎng)-文獻(xiàn)中產(chǎn)品應(yīng)用案例擴(kuò)增潛力干細(xì)胞-滋養(yǎng)層干細(xì)胞來(lái)源的滋養(yǎng)層類器官義翹神州50ng/mLHumanHGF(SinoBiological,10463-HNAS)50ng/mLHumanEGF80ng/mLHumanR-spondin1(SinoBiological,11083-HNAS)培養(yǎng)中用到的細(xì)胞因子100ng/mLHumanFGF2DegongRuan;etal./10.1016/j.xcrm.2022.100849.滋養(yǎng)層類器官類器官培養(yǎng)相關(guān)產(chǎn)品數(shù)據(jù)義翹神州活性比較數(shù)據(jù)批間一致性數(shù)據(jù)Measuredbyitsabilitytoinduceactivationof?cateninresponseinaTopflashLuciferaseassayusingHEK293Thumanembryonickidneycells.RSPO1(Cat#:11083-HNAS)國(guó)外知名品牌義翹神州義翹神州批次1義翹神州批次2義翹神州批次3活性比較數(shù)據(jù)批間一致性數(shù)據(jù)MeasuredbyitsabilitytoneutralizeTGF-betamediatedinhibitiononMv-1-Lucellproliferation.HGF(Cat#:10463-HNAS)義翹神州國(guó)外知名品牌義翹神州批次1義翹神州批次2義翹神州批次3腸道類器官培養(yǎng)-文獻(xiàn)中產(chǎn)品應(yīng)用案例1義翹神州AdvancedDMEM/F12medium50ng/mLMouseEGF(SinoBiological,50482-MNCH)100ng/mLMouseNoggin(SinoBiological,50688-M02H)50mg/mLHumanR-spondin1(SinoBiological,11083-HNAS)培養(yǎng)主要組成結(jié)直腸癌組織分離培養(yǎng)包埋在Matrigel中接種到12孔板上添加類器官培養(yǎng)基每2~3天更換新鮮培養(yǎng)基結(jié)直腸癌類器官用于：藥敏試驗(yàn)藥物作用機(jī)制研究Fenget/10.1038/s41388-023-02676-9.結(jié)直腸癌類器官--結(jié)直腸癌患者治療效果的研究腸道類器官培養(yǎng)-文獻(xiàn)中產(chǎn)品應(yīng)用案例2義翹神州AdvancedDMEM/F12medium50ng/mLMouseEGF(SinoBiological,50482-MNCH)100ng/mLMouseNoggin(SinoBiological,50688-M02H)500ng/mLHumanR-spondin1(SinoBiological,11083-HNAS)培養(yǎng)主要組成結(jié)直腸癌組織分離培養(yǎng)包埋在Matrigel中接種到48孔板上添加類包含藥物的培養(yǎng)基每3天更換新鮮培養(yǎng)基結(jié)直腸癌類器官用于：疾病研究藥物作用機(jī)制研究DakuiLuoet/10.1186/s40164-023-00440-z.100ng/mLHumanFGF10(SinoBiological,10573-HNAE)結(jié)直腸癌類器官--疾病研究不同時(shí)間點(diǎn)顱咽管瘤類器官的形態(tài)

腦類器官培養(yǎng)-文獻(xiàn)中產(chǎn)品應(yīng)用案例義翹神州10ng/mLHumanFGF10(SinoBiological,10573-HNAE)10ng/mLHumanEGF(SinoBiological,10605-HNAE)培養(yǎng)中用到的細(xì)胞因子X(jué)iao-YanTang;etal./10.1038/s41392-022-01024-9.腦腫瘤類器官類器官培養(yǎng)相關(guān)產(chǎn)品數(shù)據(jù)義翹神州CellproliferationassayusingBaF3mousepro-BcellstransfectedwithhumanFGFR2b.FGF10(Cat#:10573-HNAE)活性比較數(shù)據(jù)國(guó)外知名品牌義翹神州高純度（≥95%）CellproliferationassayusingBaF3mousepro-BcellstransfectedwithhumanFGFR2b.FGF7/KGF(Cat#:10210-H07E)活性比較數(shù)據(jù)國(guó)外知名品牌義翹神州高純度（≥95%）類器官培養(yǎng)相關(guān)產(chǎn)品數(shù)據(jù)義翹神州

InhibitproliferationofMPC-11cells.>1000U/mg活性比較數(shù)據(jù)義翹神州國(guó)外知名品牌

GMP級(jí)HumanActivinA

(Cat#:GMP-10429-HNAH)高純度（≥95%）CellproliferationassayusingTF-1humanerythroleukemiccells.>30,000Units/μg批間一致性數(shù)據(jù)義翹神州批次1義翹神州批次2

GMP級(jí)HumanOSM(Cat#:GMP-10452-HNAH)高純度（≥95%）經(jīng)不同類器官培養(yǎng)驗(yàn)證的細(xì)胞因子義翹神州人腸癌類器官人結(jié)直腸類器官HumanintestinalcancerorganoidswereculturedwithRSPO1(11083-HNAS),EGF(50482-MNCH),NOG(50688-M02H).(Routinelytested).DataprovidedbyD1MedicalTechnologyHumancolorectumorganoidswereculturedwithRSPO1(11083-HNAS),EGF(50482-MNCH),NOG(50688-M02H).(Routinelytested).DataprovidedbyD1MedicalTechnology.義翹神州人肺癌類器官人肺類器官HumanlungcancerorganoidswereculturedwithFGF2(10014-HNAE),FGF4(16043-HNAE),FGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.HumanlungorganoidswereculturedwithFGF2(10014-HNAE),FGF4(16043-HNAE),FGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.經(jīng)不同類器官培養(yǎng)驗(yàn)證的細(xì)胞因子義翹神州人肝癌類器官人膽管癌類器官HumanlivercancerorganoidswereculturedwithFGF2(10014-HNAE),HGF(10463-HNAS),FGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),TGFB1(10804-HNAC),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.HumancholangiocarcinomasorganoidswereculturedwithFGF2(10014-HNAE),HGF(10463-HNAS),FGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.經(jīng)不同類器官培養(yǎng)驗(yàn)證的細(xì)胞因子義翹神州人腎癌類器官人腎類器官HumankidneycancerorganoidswereculturedwithFGF2(10014-HNAE),FGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.HumankidneyorganoidswereculturedwithFGF7(10210-H07E),EGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS),HGF(10463-HNAS),FGF4(16043-HNAE).(Routinelytested).DataprovidedbyD1MedicalTechnology.經(jīng)不同類器官培養(yǎng)驗(yàn)證的細(xì)胞因子義翹神州人胃癌類器官人胃類器官HumangastriccancerorganoidswereculturedwithEGF(50482-MNCH),

FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnologyHumanstomachorganoidsorganoidswereculturedwithEGF(50482-MNCH),FGF10(10573-HNAE),NOG(50688-M02H),RSPO1(11083-HNAS).(Routinelytested).DataprovidedbyD1MedicalTechnology.經(jīng)不同類器官培養(yǎng)驗(yàn)證的細(xì)胞因子義翹神州人卵巢癌類器官人小腸類器官HumansmallintestinalorganoidswereculturedwithIL22(13059-HNAE),FGF10(10573-HNAE),EGF(50482-MNCH),NOG(50688-M02H).(Routinelytested).DataprovidedbyD1MedicalTechnology.Humanovarianorg